References
3. Ojo A, Balogun S, Williams O, et al. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulm Med 2020;5:1–10.
6. Lopez L, Hart L, Katz M. Racial and ethnic health disparities related to COVID-19. JAMA 2021;325:719–720.
7. Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute covid-19 in primary care. Br Med J 2020;370:1–8.
9. Baig AM. Chronic COVID syndrome: need for an appropriate medical terminology for long-COVID and COVID long-haulers. J Med Virol 2021; 93:2555–2556.
10. Baig AM. Deleterious outcomes in long-hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem Neurosci 2020;11:4017–4020.
11. Aucott J, Rebman A. Long-haul COVID: heed the lessons from other infection-triggered illnesses. Lancet 2021;397:967–968.
13. Barker-Davies R, O’Sullivan O, Senaratne K, et al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med 2020;54:949–959.
14. Carruthers B, van de Sande M, De Meirleir K, et al. Myalgic encephalomyelitis: international consensus criteria: review. J Intern Med 2011;270:327–338.
15. Pan A, Liu L, Wang C, et al. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA 2020;323:1915–1923.
16. Pascarella G, Strumia A, Piliego C, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020;288:192–206.
17. Lai C, Shih T, Ko W, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020;55:1–9.
18. Cheng J, Huang C, Zhang G, et al. Epidemiological characteristics of novel coronavirus pneumonia in Henan. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43:327–331.
19. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer 2018;6:56–70.
20. Chousterman B, Swirski F, Weber G. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol 2017;39:517–528. .
21. Landi F, Gremese E, Bernabei R, et al. Post-COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clin Exp Res 2020;32:1613–1620.
22. Bonow R, O’Gara P, Yancy C. Cardiology and COVID-19. JAMA 2020; 324:1131–1132.
23. Madjid M, Safavi-Naeini P, Solomon S, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol 2020;5:831–840.
24. Bikdeli B, Madhavan M, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020;75:2950–2973.
25. Inciardi R, Lupi L, Zaccone G, et al. Cardiac involvement in a patient With coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:819–824.
26. Puntmann V, Carerj M, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1265–1273.
27. Giustino G, Croft L, Oates C, et al. Takotsubo cardiomyopathy in COVID-19. J Am Coll Cardiol 2020;76:628–629.
28. Dweck M, Bularga A, Hahn R, et al. Global evaluation of echocardiography in patients with COVID-19. Eur Heart J Cardiovasc Imag 2020;21:949–958.
29. Park J, Moon J, Sohn K, et al. Two fatal cases of stress-induced cardiomyopathy in COVID-19 patients. J Cardiovasc Imag 2020;28:300–303.
30. Lai P, Lancet E, Weiden M, et al. Characteristics associated with out-of-hospital cardiac arrests and resuscitations during the novel coronavirus disease 2019 pandemic in New York City. JAMA Cardiol 2020;5:1154–1163.
31. Shinkai K, Bruckner A. Dermatology and COVID-19. JAMA 2020;324: 1133–1134.
32. Sernicola A, Alaibac M. How to deal with post-viral cutaneous eruptions in the era of coronavirus infection. Front Med 2020;7:224.
33. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020;34:212–213.
34. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020;183:71–77.
35. Droesch C, Do M, DeSancho M, et al. Livedoid and purpuric skin eruptions associated with coagulopathy in severe COVID-19. JAMA Dermatol 2020; 156:1–3.
36. Zhang Y, Cao W, Xiao M, et al. Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia. Zhonghua Xue Ye Xue Za Zhi 2020;41:302–307.
37. Yao X, Li T, He Z, et al. A pathological report of three COVID-19 cases by minimal invasive autopsies. Zhonghua Bing Li Xue Za Zhi 2020;49: 411–417.
38. Roca-Ginés J, Torres-Navarro I, Sánchez-Arráez J, et al. Assessment of acute acral lesions in a case series of children and adolescents during the COVID-19 pandemic. JAMA Dermatol 2020;156:992–998.
39. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720.
40. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J (Engl) 2020;133:1261–1267.
41. Kliger A, Silberzweig J. Mitigating risk of COVID-19 in dialysis facilities. Clin J Am Soc Nephrol 2020;15:707–709.
 
42. Winkelmayer W, Khairallah P, Charytan D. Nephrology and COVID-19. JAMA 2020;324:1137–1138.
43. Santoriello D, Khairallah P, Bomback A, et al. Postmortem kidney pathology findings in patients with COVID-19. J Am Soc Nephrol 2020; 31:2158–2167.
44. Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 2020;98:219–227.
45. Chan L, Chaudhary K, Saha A, et al. AKI in hospitalized patients with COVID-19. J Am Soc Nephrol 2021;32:151–160.
46. Loupy A, Aubert O, Reese P, et al. Organ procurement and transplantation during the COVID-19 pandemic. Lancet 2020;395:e95–e96.
47. Boyarsky B, Werbel W, Durand C, et al. Early national and center-level changes to kidney transplantation in the United States during the COVID-19 epidemic. Am J Transplant 2020;20:3131–3139.
48. Imam S, Lao W, Reddy P, et al. Is SARS-CoV-2 (COVID-19) postviral olfactory dysfunction (PVOD) different from other PVOD? World J Otorhinolaryngol Head Neck Surg 2020;6:S26–S32.
49. Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a casecontrolled study. BioMed Cent Neurol 2011;11:1–7.
50. Hives L, Bradley A, Richards J, et al. Can physical assessment techniques aid diagnosis in people with chronic fatigue syndrome/myalgic encephalomyelitis? A diagnostic accuracy study. BMJ Open 2017;7:e017521.
51. Kida S, Pantazis A, Weller R. CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol Appl Neurobiol 1993;19:480–488.
52. Perrin R, Riste L, Hann M, et al. Into the looking glass: post-viral syndrome post COVID-19. Med Hypotheses 2020;144:110055.
53. Politi L, Salsano E, Grimaldi M. Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia. JAMA Neurol 2020;77:1028–1029.
54. Zubair A, McAlpine L, Gardin T, et al. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 2020;77:1018–1027.
55. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683–690.
56. Josephson S, Kamel H. Neurology and COVID-19. JAMA 2020;324: 1139–1140.
57. Merkler A, Parikh N, Mir S, et al. Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza. JAMA Neurol 2020;77:1–7.
58. Spence J, Greitas G, Pettigrew L, et al. Mechanisms of stroke in COVID-19. Cerebrovasc Dis 2020;49:451–458.
59. Carod-Artal F. Neurological complications of coronavirus and COVID-19. Rev Neurol 2020;70:311–322.
60. Poyiadji N, Shahin G, Noujaim D, et al. Covid-19 associated acute hemorrhagic necrotizing encephalopathy. CT and MRI features. Radiology 2020;296: E119–E120.
61. Solomon I, Normandin E, Bhattacharyya S, et al. Neuropathological features of Covid-19. N Engl J Med 2020;383:989–992.
62. Gupta S, Hayek S, Wang W, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 2020;180:1436–1446.
63. Kuderer N, Choueiri T, Shah D, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020;395:1907–1918.
64. Disis ML. Oncology and COVID-19. JAMA 2020;324:1141–1142.
65. Lee L, Cazier J, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020;395:1919–1926.
66. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–733.
67. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–513.
68. Raptis C, Hammer M, Short R, et al. Chest CT and coronavirus disease (COVID-19): a critical review of the literature to date. Am J Roentgenol 2020;215:839–842.
69. Thompson B, Chambers R, Liu K. Acute respiratory distress syndrome. N Engl J Med 2017;377:562–572.
70. Ackermann M, Verleden S, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020;383:120–128.
71. Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol 2020;92:612–617.
72. Wong K, Antonio G, Hui D, et al. Severe acute respiratory syndrome: thin-section computed tomography features, temporal changes, and clinicoradiologic correlation during the convalescent period. J Comput Assist Tomogr 2004;28:790–795.
73. Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol 2020;138:575–578.
74. Bressler NM. Ophthalmology and COVID-19. JAMA 2020;324:1143–1144.
75. Zeng W, Wang X, Li J, et al. Association of daily wear of eyeglasses with susceptibility to coronavirus disease 2019 infection. JAMA Ophthalmol 2020;138:1196–1199.
76. Maragakis L. Eye protection and the risk of coronavirus disease 2019: does wearing eye protection mitigate risk in public, non–health care settings? JAMA Ophthalmol 2020;138:1199–1200.
77. Druss B. Addressing the COVID-19 pandemic in populations with serious mental illness. JAMA Psychiatry 2020;77:891–892.
78. Rogers J, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020;7:611–627.
79. Noone R, Cabassa J, Gardner L, et al. Letter to the editor: new onset psychosis and mania following COVID-19 infection. J Psychiatr Res 2020;130:177–179.
80. Ladani A, Loganathan M, Danve A. Managing rheumatic diseases during COVID-19. Clin Rheumatol 2020;39:3245–3254.
81. Ahmed M, Advani S, Moreira A, et al. Multisystem inflammatory syndrome in children: a systematic review. EClinicalMedicine 2020;26:100527.
82. Ehrenfeld M, Tincani A, Andreoli L, et al. Covid-19 and autoimmunity. Autoimmun Rev 2020;19:102597.
83. Gagiannis D, Steinestel J, Hackenbroch C, et al. COVID-19-induced acute respiratory failure: an exacerbation of organ-specific autoimmunity? medRxiv 2020. DOI: 10.1101/2020.04.27.20077180.
84. Zulfiqar A, Lorenzo-Villalba N, Hassler P, et al. Immune thrombocytopenic purpura in a patient with Covid-19. N Engl J Med 2020;382:e43.
85. Tsao H, Chason H, Fearon D. Immune thrombocytopenia (ITP) in a pediatric patient positive for SARS-CoV-2. Pediatrics 2020;146:e20201419.
86. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020;382:e38.
87. Harzallah I, Debliquis A, Drénou B. Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost 2020;18:2064–2065.
88. Bowles L, Platton S, Yartey N, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med 2020;383: 288–290.
89. Massachusetts General Hospital, and ZOE. COVID Symptom Study. Continue the fight against COVID.
https://covid.joinzoe.com/us. Accessed February 7, 2021.
90. Lan L, Xu D, Ye G, et al. Positive RT-PCR test results in patients recovered from COVID-19. JAMA 2020;323:1502–1503.
91. Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603–605.
92. Coraci D, Fusco A, Frizziero A, et al. Global approaches for global challenges: the possible support of rehabilitation in the management of COVID-19. J Med Virol 2020;92:1739–1740.
93. Lazzeri M, Lanza A, Bellini R, et al. Respiratory physiotherapy in patients with COVID-19 infection in acute setting: a Position Paper of the Italian Association of Respiratory Physiotherapists (ARIR). Monaldi Arch Chest Dis 2020;90:163–168.
94. Boldrini P, Kiekens C, Bargellesi S, et al. First impact on services and their preparation. "Instant paper from the field" on rehabilitation answers to the Covid-19 emergency. Eur J Phys Rehabil Med 2020;56:319–322.
95. Stam H, Stucki G, Bickenbach J. Covid-19 and post intensive care syndrome: a call for action. J Rehabil Med 2020;52:1–4.
96. Zhang P, Li J, Liu H, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res 2020;8:8.
97. Marshall M. The lasting misery of coronavirus long-haulers. Nature 2020; 585:339–341.
98. Hu Y, Li W, Gao T, et al. The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination. J Virol 2017;91:e02143–16.
99. Mitrani R, Dabas N, Goldberger J. COVID-19 cardiac injury: implications for long-term surveillance and outcomes in survivors. Heart Rhythm 2020; 17:1984–1990.
100. Lindner D, Fitzek A, Bräuninger H, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol 2020;5:1281–1285.
101. Del Rio C, Collins L, Malani P. Long-term health consequences of COVID19. JAMA 2020;324:1723–1724.
102. Whittaker E, Bamford A, Kenny J, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020;324:259–269.
103. Brancatella A, Ricci D, Viola N, et al. Subacute thyroiditis after Sars-COV-2 infection. J Clin Endocrinol Metab 2020;105:2367–2370.
104. Brancatella A, Ricci D, Cappellani D, et al. Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? Insights from a case series. J Clin Endocrinol Metab 2020;105:dgaa537.
105. Bruchfeld A. The COVID-19 pandemic: consequences of nephrology. Nat Rev Nephrol 2021;17:81–82.
106. Das K, Lee E, Singh R, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging 2017; 27:342–349.
107. Wang J, Wang B, Yang J, et al. Advances in the research of mechanism of pulmonary fibrosis induced by corona virus disease 2019 and the corresponding therapeutic measures. Chin J Burns 2020;36:691–697.
108. Zhao Y, Shang Y, Song W, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 2020;25:100463.
109. Huang Y, Tan C, Wu J, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res 2020;21:163.
110. Ngai J, Ko F, Ng S, et al. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology 2010;15:543–50.
111. Hui D, Joynt G, Wong K, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax 2005;60:401–409.
113. Troyer E, Kohn J, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun 2020;87:34–39.
114. Ray C, Weir W, Phillips S, et al. Development of a measure of symptoms in chronic fatigue syndrome: the profile of fatigue-related symptoms(pfrs). Psychol Health 1992;7:27–43.
115. Wilson C. Concern coronavirus may trigger post-viral fatigue syndromes. New Sci 2020;246:10–11.
116. Montoya J, Holmes T, Anderson J, et al. Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proc Natl Acad Sci USA 2017;114:7150–7158.
117. Öngür D, Perlis R, Goff D. Psychiatry and COVID-19. JAMA 2020;324: 1149–1150.
118. Galea S, Merchant RM, Lurie N. The mental health consequences of COVID-19 and physical distancing: the need for prevention and early intervention. JAMA Intern Med 2020;180:817.
119. Feldstein L, Rose E, Horwitz S, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020;383:334–346.
120. Chiotos K, Bassiri H, Behrens E, et al. Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series. J Pediatr Infect Dis Soc 2020;9:393–398.
121. Demeco A, Marotta N, Barletta M, et al. Rehabilitation of patients post-COVID-19 infection: a literature review. J Int Med Res 2020;48: 300060520948382.
123. Fosbøl E, Butt J, Østergaard L, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA 2020;324:168–177.
124. Liu K, Zhang W, Yang Y, et al. Respiratory rehabilitation in elderly patients with COVID-19: a randomized controlled study. Complement Ther Clin Pract 2020;39:101166.